Loading…
Welcure Drugs & Pharmaceuticals (BSE 524661)₹0.1900−5.00%Pharmaceuticals
In the Mar 2026 quarter (standalone), Welcure Drugs & Pharmaceuticals reported sales of ₹0 Cr, down 100.0% from Mar 2025, and net profit of −₹49.90 Cr, down 1,768.9% year on year. For the year to Mar 2026, sales were ₹366 Cr and net profit −₹4.99 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 25.01 | 0.99 | 20.99 | 300 | 66.02 | 0.00 | 0.00 |
| Expenses | 0.00 | 0.00 | 0.00 | 22.92 | 0.99 | 20.94 | 268 | 53.81 | 0.00 | 49.82 |
| Operating Profit | 0.00 | 0.00 | 0.00 | 1.99 | 0.00 | 0.99 | 30.90 | 10.97 | 0.00 | −49.84 |
| OPM % | — | — | — | 7.0% | 10.1% | 3.0% | 10.1% | 17.0% | — | — |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 0.00 | 0.00 | 1.01 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 0.00 | 0.00 | 2.01 | 0.00 | 3.01 | 31.03 | 11.02 | 1.01 | −50.09 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 56.0% | 0.0% | 25.0% | 25.0% | 25.0% | 0.0% |
| Net Profit | 0.00 | 0.00 | 0.00 | 1.99 | 0.00 | 2.99 | 22.95 | 7.98 | 0.99 | −49.90 |
| EPS (Rs) | 0.00 | 0.00 | −0.01 | 0.00 | 0.00 | 0.01 | 0.18 | 0.06 | 0.00 | −0.39 |
| Mar 2016 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 24.99 | 366 | 366 |
| Expenses | 0.00 | 0.00 | 0.00 | 23.93 | 371 | 372 |
| Operating Profit | 0.00 | 0.00 | 0.00 | 0.99 | −6.98 | −7.97 |
| OPM % | 40.1% | — | — | 4.0% | −1.9% | −2.2% |
| Other Income | 0.00 | 0.00 | 0.00 | 2.01 | 0.99 | 1.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 0.00 | 0.00 | 3.01 | −5.01 | −7.03 |
| Tax % | 0.0% | 0.0% | 0.0% | 22.0% | 0.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 0.00 | 0.00 | 0.00 | 1.99 | −4.99 | −17.98 |
| EPS (Rs) | 0.00 | 0.00 | 0.00 | 0.01 | −0.03 | −0.15 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11.99 | 11.99 | 12.00 | 11.99 | 11.99 | 11.99 | 11.99 | 11.99 | 13.00 | 13.00 | 112 | 124 |
| Reserves | −11.99 | −11.99 | −12.00 | −11.99 | −11.99 | −11.99 | −11.99 | −11.99 | −11.99 | −11.99 | −9.96 | −27.03 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 123 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 41.19 | 415 |
| Total Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 1.01 | 268 | 511 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 268 | 510 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 144 | 144 |
| Trade receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.95 | 213 |
| Cash & equivalents | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 |
| Total Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 1.01 | 268 | 511 |
| Mar 2016 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | — | — | −221 | 1.99 |
| Cash from investing activity | — | — | 0.00 | −1.01 |
| Cash from financing activity | — | — | 222 | 0.00 |
| Net cash flow | — | — | 0.00 | 0.00 |
| Capex | 0.00 | 0.00 | 0.01 | 0.00 |
| Free cash flow | — | — | −223 | 2.01 |
| CFO / OP % | — | — | −22,890.0% | −25.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 0 | 0 | 0 | 0 | 0 | — | — | 283 | 214 |
| Inventory days | — | — | — | — | — | — | — | 2,554 | 162 |
| Days payable | — | — | — | — | — | — | — | 52 | 226 |
| Cash conversion cycle | 0 | 0 | 0 | 0 | 0 | — | — | 2,784 | 150 |
| Working capital days | −875 | 37 | 82 | 74 | 47 | — | — | 2,093 | −55 |
| ROCE % | — | — | 120.0% | −67.0% | 0.0% | 10.0% | −13.0% | 3.0% | −3.0% |
For the Mar 2026 quarter, Welcure Drugs & Pharmaceuticals reported sales of ₹0 Cr, down 100.0% year on year and net profit of −₹49.90 Cr, down 1,768.9% year on year.
Welcure Drugs & Pharmaceuticals' sales for the year to Mar 2026 were ₹366 Cr; over the last twelve months they were ₹366 Cr.
Net profit for the year to Mar 2026 was −₹4.99 Cr, and −₹17.98 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−0.15.
Welcure Drugs & Pharmaceuticals reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹1.01 Cr.
Cash from operations was ₹1.99 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹2.01 Cr.